Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy? | LLY Stock Analysis

Parkev Tatevosian, CFA•Jun 26, 2026

Summary

Parkev's main thesis is that Eli Lilly is an undervalued pharmaceutical powerhouse that offers more than just its well-known weight loss treatments. He emphasizes that the company's core value lies in its ability to innovate and deliver treatments for various diseases, which generates sustainable billions in revenue and profit. Parkev highlights the company's historical ability to convert research and development (R&D) spending into high-margin profits, noting that operating margins have surged from 10% in 2017 to over 40% recently.

From a market outlook perspective, Parkev views pharmaceutical stocks as a crucial defensive play. Unlike cyclical sectors like the automotive industry, healthcare needs are independent of economic cycles, making Eli Lilly a 'diversifying factor' for portfolios. He specifically mentions that for investors heavily allocated to the AI sector, Eli Lilly provides an uncorrelated return stream that reduces overall portfolio risk.

Regarding valuation, Parkev provides specific figures to support his bullish stance. He notes the stock is trading at a forward price-to-earnings (P/E) ratio of 30 and a forward price-to-operating cash flow of 29.4, which he considers reasonable for a company with such high growth and margins. Most importantly, his discounted cash flow (DCF) analysis yields a fair value of $1,443 per share, significantly higher than the current market price of approximately $1,114.

Eli Lilly (LLY): Parkev highlights the success of Jaypirca in leukemia trials and the promising Phase 3 results of Retatrutide for obesity, which showed a 28% average weight loss. He notes that the company is not resting on its laurels but is actively developing better distribution methods and more effective treatments to reach a broader global patient base. Parkev concludes that with a fair value calculation of $1,443, the stock is currently undervalued at its $1,114 price point.

Mentioned Stocks

LLY

Sentiment: BUYAction: RECOMMENDED

Reasoning: Parkev identifies Eli Lilly as an excellent buy due to its massive growth in weight loss treatments and oncology innovation (specifically Jaypirca). He notes that the company has improved its operating margins from 10% to over 40% since 2017. Most significantly, Parkev uses a discounted cash flow model to estimate a fair value of $1,443 per share, which suggests significant upside from the current market price of $1,114. He also values the stock's low correlation with the macroeconomy as a risk-reduction tool for portfolios.

Loading chart...